Key Takeaways
Topics Covered
For 25+ years, Niagen Bioscience been developing rigorous standards which has led to our ability to ensure a pure and high quality NR-Cl, —underwriting the research, patenting the molecule and its production processes, and supplying the quality-tested ingredient used in the majority of peer-reviewed human studies on NR.
That foundation just reached a new milestone.
In March 2026, the U.S. Pharmacopeia (USP) published a monograph for nicotinamide riboside chloride (NRCl)—the first compendial standard for any NAD+ precursor, and the ingredient most consumers know commercially as Niagen®.
This is a significant development—not just for Niagen Bioscience, but for anyone trying to make informed decisions in a supplement category that has, until now, operated without a clear quality benchmark.
What Is a USP Monograph?
The United States Pharmacopeia (USP) is an independent, nonprofit, scientific standards-setting organization that has been publishing ingredient quality standards for more than 200 years. USP standards are recognized by the FDA, international regulatory authorities, and U.S. courts as the official reference for ingredient identity, purity, and potency.
A USP Monograph is a published compendial standard for a specific ingredient. It defines:
- Identity — what the ingredient chemically is
- Purity — what it can and cannot contain
- Potency — what it must deliver
- Analytical methods — how all of the above are tested
In the pharmaceutical world, USP Monographs are legally required for all active pharmaceutical ingredients. In the dietary supplement world, they are voluntary—but meaningful. If a supplement brand claims its ingredient meets a USP Monograph, it must have the substantiation to back that up. Otherwise, the product can be deemed misbranded.
In a category as fragmented and uneven as NAD+ supplementation, this is the kind of standard that actually separates serious ingredient science from marketing copy.
First for NR. First for the Novel NAD+ Precursor Category.
Until March, no novel NAD+ precursor had a USP Monograph. Not NR. Not NMN. Not NAD+ itself.
NR Chloride is now the first.
This isn't a minor distinction. Publishing a USP Monograph requires years of submitted scientific data, validated analytical methods, and peer review by USP expert committees. It's a process measured in years, not months, and it is sponsored by organizations willing to invest the scientific and financial resources to bring an ingredient standard forward.
Niagen Bioscience is the sponsor of the NR Chloride monograph. The identity, specifications, and testing methods codified in the standard are built on the same analytical framework Niagen Bioscience has used to produce and release Niagen for more than two decades.
The NR Chloride USP Monograph is a direct reflection of the scientific and quality infrastructure Niagen Bioscience has built for 25+ years. The standard was made possible by the evidence base behind Niagen.
Niagen Is NR Chloride. NR Chloride Is the Standard.
This is the point most worth understanding:
Niagen® is the branded, patented form of nicotinamide riboside chloride. The active ingredient in every bottle of Tru Niagen is Niagen NR—the same chemical entity (NRCl) that is now the subject of the new USP compendial standard.
The research record behind that standard is, in substantial part, a Niagen research record:
- 500+ peer-reviewed preclinical and clinical studies have been published on NR overall
- 40+ peer-reviewed human studies have been conducted using Niagen NR specifically
- 75% of all published NR studies used Niagen as the form of NR studied
- 300+ global research collaborations have been established through Niagen Bioscience's External Research Program, supplying Niagen to leading universities and research institutions worldwide
This is the most extensive body of clinical research on any commercially available NAD+ precursor. It is also the body of research that made the pharmacopeial standard possible.
Why This Matters for Nicotinamide Riboside (NR)
A USP Monograph doesn't change what's already in a bottle of Tru Niagen. What it changes is the bar for everything else.
In February 2025, Niagen Bioscience's ISO 17025–accredited laboratory published the findings of its Market Surveillance Program—a quantitative analysis of 39 NR products purchased from Amazon and direct-to-consumer websites. The findings were, frankly, alarming:
- Only 13% of NR supplements tested fully met or exceeded their label claims
- 36% contained virtually no NR at all (less than 1% of the claimed amount)
- All four products tested at the highest claimed dosage (1,500 mg) had no detectable NR
You can read the full breakdown in our post on how 87% of NR supplements fail to meet their label claims.
The new USP Monograph for NR Chloride doesn't automatically fix this. It does, however, give the category a formal, compendial benchmark against which product quality can be measured. Any product that claims to adhere to the monograph must substantiate that claim. Any product that doesn't will increasingly stand out as the market matures.
What This Means for Tru Niagen Consumers
If you take Tru Niagen, here is what the NR Chloride USP Monograph signals:
- The ingredient in your Tru Niagen is the ingredient the standard is written for. Niagen is nicotinamide riboside chloride—the compound codified in the new USP compendial standard.
- The quality infrastructure hasn't changed—because it didn't need to. Every lot of Tru Niagen is tested for identity, potency, and purity. At least 19 internal and third-party tests are conducted in the production and release of Tru Niagen. Laboratories are ISO/IEC 17025:2017 accredited. Every bottle is fully traceable through our certificate of analysis transparency platform.
- The evidence base behind the standard is the evidence behind Niagen. The scientific substantiation that underpins the new USP Monograph didn't emerge from a vacuum. Niagen Bioscience has spent over two decades developing rigorous standards, which has led to our ability to ensure a pure and high quality NR-Cl with Niagen.—You were already choosing the most-studied, most-scrutinized form of NR on the market. The USP Monograph simply formalizes what Tru Niagen consumers have been choosing all along.
The Bigger Picture for NAD+ Precursors
NAD+ supplementation has, for the last several years, lived in an evolving space between serious science and biohacking hype. The science on NR itself is real, peer-reviewed, and growing. The supplement market selling NR, NMN, and NAD+ products to consumers has been—by the data—considerably less rigorous.
A USP Monograph for NR Chloride is the clearest signal yet that the regulatory and scientific infrastructure of the NAD+ category is maturing. Standards are being published. Ingredients are being codified. The difference between a product backed by decades of human research and a product assembled to ride a trend is, increasingly, measurable.
That's what a standard does. It draws a line. And the line for NR now runs directly through Niagen.
Want the full scientific breakdown? Read our companion deep-dive on AboutNAD: Nicotinamide Riboside Chloride Now Has a USP Monograph—Here's What That Means.
Ready to take the form of NR behind the standard?
Tru Niagen is powered by Niagen® NR—nicotinamide riboside chloride—the ingredient used in more published human clinical studies than any other patented NAD+ precursor, and the form now codified as the USP compendial standard.